Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma
Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Com...
Gespeichert in:
| Veröffentlicht in: | Oncology 1998-07, Vol.55 (4), p.276-283 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 283 |
|---|---|
| container_issue | 4 |
| container_start_page | 276 |
| container_title | Oncology |
| container_volume | 55 |
| creator | Okusaka, Takuji Okada, Shuichi Ishii, Hiroshi Ikeda, Masafumi Nakasuka, Hidekazu Nagahama, Hiroyasu Iwata, Ryoko Furukawa, Hiroyoshi Takayasu, Kenichi Nakanishi, Yukihiro Sakamoto, Michiie Hirohashi, Setsuo Yoshimori, Masayoshi |
| description | Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as ≧50% reduction and/or ≧50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC. |
| doi_str_mv | 10.1159/000011863 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_220896521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>676601991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-ead86a280c60eda2211930bd7120e6d9a4e0ad0af2051e6e332a331bf5caf3bd3</originalsourceid><addsrcrecordid>eNpt0E1Lw0AQBuBFlFqrB88ihOLFQ3Q_km1ylKBWKBS0XryESTJrU_Pl7gbpv3e1oV6cyx7ehxn2JeSc0RvGwviWumEskuKAjFnAhU-54IdkTKmgPg9YcExOjNk4NQsDOSKjWEoRsHBMnlcaGgPaoi6h8pI11q1do4Zu632Vdu29lU1rLNiy8V5sWUMFNWpPtdqbYwe2zbGq-gq0l4DOna3hlBwpqAyeDe-EvD7cr5K5v1g-PiV3Cz8XkbA-QhFJ4BHNJcUCOGcsFjQrZoxTlEUMAVIoKChOQ4YSheAgBMtUmIMSWSEmZLrb2-n2s0dj003b68adTDmnUSxDzhy63qFct8ZoVGmn3S_0NmU0_eku3Xfn7OWwsM9qLPZyKMvlV0MOJodKueby0uwZ57GbyLGLHfsA_Y767-BwZPpvukwWvyDtCiW-AXHEiug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220896521</pqid></control><display><type>article</type><title>Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma</title><source>MEDLINE</source><source>Karger Journals</source><creator>Okusaka, Takuji ; Okada, Shuichi ; Ishii, Hiroshi ; Ikeda, Masafumi ; Nakasuka, Hidekazu ; Nagahama, Hiroyasu ; Iwata, Ryoko ; Furukawa, Hiroyoshi ; Takayasu, Kenichi ; Nakanishi, Yukihiro ; Sakamoto, Michiie ; Hirohashi, Setsuo ; Yoshimori, Masayoshi</creator><creatorcontrib>Okusaka, Takuji ; Okada, Shuichi ; Ishii, Hiroshi ; Ikeda, Masafumi ; Nakasuka, Hidekazu ; Nagahama, Hiroyasu ; Iwata, Ryoko ; Furukawa, Hiroyoshi ; Takayasu, Kenichi ; Nakanishi, Yukihiro ; Sakamoto, Michiie ; Hirohashi, Setsuo ; Yoshimori, Masayoshi</creatorcontrib><description>Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as ≧50% reduction and/or ≧50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000011863</identifier><identifier>PMID: 9663415</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Hepatocellular - diagnostic imaging ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Clinical Study ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Infusions, Intra-Arterial ; Liver Neoplasms - diagnostic imaging ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Maleic Anhydrides - administration & dosage ; Maleic Anhydrides - adverse effects ; Maleic Anhydrides - therapeutic use ; Medical sciences ; Middle Aged ; Polystyrenes - administration & dosage ; Polystyrenes - adverse effects ; Polystyrenes - therapeutic use ; Time Factors ; Tomography, X-Ray Computed - methods ; Treatment Outcome ; Tumors ; Zinostatin - administration & dosage ; Zinostatin - adverse effects ; Zinostatin - analogs & derivatives ; Zinostatin - therapeutic use</subject><ispartof>Oncology, 1998-07, Vol.55 (4), p.276-283</ispartof><rights>1998 S. Karger AG, Basel</rights><rights>1998 INIST-CNRS</rights><rights>Copyright (c) 1998 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-ead86a280c60eda2211930bd7120e6d9a4e0ad0af2051e6e332a331bf5caf3bd3</citedby><cites>FETCH-LOGICAL-c383t-ead86a280c60eda2211930bd7120e6d9a4e0ad0af2051e6e332a331bf5caf3bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2299998$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9663415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okusaka, Takuji</creatorcontrib><creatorcontrib>Okada, Shuichi</creatorcontrib><creatorcontrib>Ishii, Hiroshi</creatorcontrib><creatorcontrib>Ikeda, Masafumi</creatorcontrib><creatorcontrib>Nakasuka, Hidekazu</creatorcontrib><creatorcontrib>Nagahama, Hiroyasu</creatorcontrib><creatorcontrib>Iwata, Ryoko</creatorcontrib><creatorcontrib>Furukawa, Hiroyoshi</creatorcontrib><creatorcontrib>Takayasu, Kenichi</creatorcontrib><creatorcontrib>Nakanishi, Yukihiro</creatorcontrib><creatorcontrib>Sakamoto, Michiie</creatorcontrib><creatorcontrib>Hirohashi, Setsuo</creatorcontrib><creatorcontrib>Yoshimori, Masayoshi</creatorcontrib><title>Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma</title><title>Oncology</title><addtitle>Oncology</addtitle><description>Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as ≧50% reduction and/or ≧50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - diagnostic imaging</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Clinical Study</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Infusions, Intra-Arterial</subject><subject>Liver Neoplasms - diagnostic imaging</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Maleic Anhydrides - administration & dosage</subject><subject>Maleic Anhydrides - adverse effects</subject><subject>Maleic Anhydrides - therapeutic use</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Polystyrenes - administration & dosage</subject><subject>Polystyrenes - adverse effects</subject><subject>Polystyrenes - therapeutic use</subject><subject>Time Factors</subject><subject>Tomography, X-Ray Computed - methods</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Zinostatin - administration & dosage</subject><subject>Zinostatin - adverse effects</subject><subject>Zinostatin - analogs & derivatives</subject><subject>Zinostatin - therapeutic use</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0E1Lw0AQBuBFlFqrB88ihOLFQ3Q_km1ylKBWKBS0XryESTJrU_Pl7gbpv3e1oV6cyx7ehxn2JeSc0RvGwviWumEskuKAjFnAhU-54IdkTKmgPg9YcExOjNk4NQsDOSKjWEoRsHBMnlcaGgPaoi6h8pI11q1do4Zu632Vdu29lU1rLNiy8V5sWUMFNWpPtdqbYwe2zbGq-gq0l4DOna3hlBwpqAyeDe-EvD7cr5K5v1g-PiV3Cz8XkbA-QhFJ4BHNJcUCOGcsFjQrZoxTlEUMAVIoKChOQ4YSheAgBMtUmIMSWSEmZLrb2-n2s0dj003b68adTDmnUSxDzhy63qFct8ZoVGmn3S_0NmU0_eku3Xfn7OWwsM9qLPZyKMvlV0MOJodKueby0uwZ57GbyLGLHfsA_Y767-BwZPpvukwWvyDtCiW-AXHEiug</recordid><startdate>19980701</startdate><enddate>19980701</enddate><creator>Okusaka, Takuji</creator><creator>Okada, Shuichi</creator><creator>Ishii, Hiroshi</creator><creator>Ikeda, Masafumi</creator><creator>Nakasuka, Hidekazu</creator><creator>Nagahama, Hiroyasu</creator><creator>Iwata, Ryoko</creator><creator>Furukawa, Hiroyoshi</creator><creator>Takayasu, Kenichi</creator><creator>Nakanishi, Yukihiro</creator><creator>Sakamoto, Michiie</creator><creator>Hirohashi, Setsuo</creator><creator>Yoshimori, Masayoshi</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope></search><sort><creationdate>19980701</creationdate><title>Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma</title><author>Okusaka, Takuji ; Okada, Shuichi ; Ishii, Hiroshi ; Ikeda, Masafumi ; Nakasuka, Hidekazu ; Nagahama, Hiroyasu ; Iwata, Ryoko ; Furukawa, Hiroyoshi ; Takayasu, Kenichi ; Nakanishi, Yukihiro ; Sakamoto, Michiie ; Hirohashi, Setsuo ; Yoshimori, Masayoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-ead86a280c60eda2211930bd7120e6d9a4e0ad0af2051e6e332a331bf5caf3bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - diagnostic imaging</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Clinical Study</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Infusions, Intra-Arterial</topic><topic>Liver Neoplasms - diagnostic imaging</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Maleic Anhydrides - administration & dosage</topic><topic>Maleic Anhydrides - adverse effects</topic><topic>Maleic Anhydrides - therapeutic use</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Polystyrenes - administration & dosage</topic><topic>Polystyrenes - adverse effects</topic><topic>Polystyrenes - therapeutic use</topic><topic>Time Factors</topic><topic>Tomography, X-Ray Computed - methods</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Zinostatin - administration & dosage</topic><topic>Zinostatin - adverse effects</topic><topic>Zinostatin - analogs & derivatives</topic><topic>Zinostatin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okusaka, Takuji</creatorcontrib><creatorcontrib>Okada, Shuichi</creatorcontrib><creatorcontrib>Ishii, Hiroshi</creatorcontrib><creatorcontrib>Ikeda, Masafumi</creatorcontrib><creatorcontrib>Nakasuka, Hidekazu</creatorcontrib><creatorcontrib>Nagahama, Hiroyasu</creatorcontrib><creatorcontrib>Iwata, Ryoko</creatorcontrib><creatorcontrib>Furukawa, Hiroyoshi</creatorcontrib><creatorcontrib>Takayasu, Kenichi</creatorcontrib><creatorcontrib>Nakanishi, Yukihiro</creatorcontrib><creatorcontrib>Sakamoto, Michiie</creatorcontrib><creatorcontrib>Hirohashi, Setsuo</creatorcontrib><creatorcontrib>Yoshimori, Masayoshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okusaka, Takuji</au><au>Okada, Shuichi</au><au>Ishii, Hiroshi</au><au>Ikeda, Masafumi</au><au>Nakasuka, Hidekazu</au><au>Nagahama, Hiroyasu</au><au>Iwata, Ryoko</au><au>Furukawa, Hiroyoshi</au><au>Takayasu, Kenichi</au><au>Nakanishi, Yukihiro</au><au>Sakamoto, Michiie</au><au>Hirohashi, Setsuo</au><au>Yoshimori, Masayoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>1998-07-01</date><risdate>1998</risdate><volume>55</volume><issue>4</issue><spage>276</spage><epage>283</epage><pages>276-283</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as ≧50% reduction and/or ≧50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>9663415</pmid><doi>10.1159/000011863</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 1998-07, Vol.55 (4), p.276-283 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_proquest_journals_220896521 |
| source | MEDLINE; Karger Journals |
| subjects | Adolescent Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Clinical Study Female Gastroenterology. Liver. Pancreas. Abdomen Humans Infusions, Intra-Arterial Liver Neoplasms - diagnostic imaging Liver Neoplasms - drug therapy Liver Neoplasms - pathology Liver Neoplasms - surgery Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Maleic Anhydrides - administration & dosage Maleic Anhydrides - adverse effects Maleic Anhydrides - therapeutic use Medical sciences Middle Aged Polystyrenes - administration & dosage Polystyrenes - adverse effects Polystyrenes - therapeutic use Time Factors Tomography, X-Ray Computed - methods Treatment Outcome Tumors Zinostatin - administration & dosage Zinostatin - adverse effects Zinostatin - analogs & derivatives Zinostatin - therapeutic use |
| title | Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A59%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transarterial%20Chemotherapy%20with%20Zinostatin%20Stimalamer%20for%20Hepatocellular%20Carcinoma&rft.jtitle=Oncology&rft.au=Okusaka,%20Takuji&rft.date=1998-07-01&rft.volume=55&rft.issue=4&rft.spage=276&rft.epage=283&rft.pages=276-283&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000011863&rft_dat=%3Cproquest_pubme%3E676601991%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220896521&rft_id=info:pmid/9663415&rfr_iscdi=true |